[3]Koshy N, Quispe D, Shi R, et al. Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast. 2010 Jun;19(3...
Treatment of triple negative breast cancer (TNBC) is a clinically challenging problem due to intriguing clinical and pathologic features of TNBC and natural or induced resistance to existing therapies. However, a great understanding of features of TNBC particularly associated with BRCA mutations has led...
Chemotherapy has long been the cornerstone of treatment for triple-negative breast cancer. Recently, the integration of PARPis into treatment regimens has shown promise, particularly in patients with BRCA1/2 mutations, due to their impaired DNA repair mechanisms via HR [15]. PARP inhibitors, when ...
Assessing the risk of uterine serous carcinoma in survivors of triple negative breast cancer: Is BRCA1 the link? 评估三阴性乳腺癌幸存者患子宫浆液性癌的风险:BRCA1是联系吗? First Author: William Manning Background Uterine ...
1.Hurvitz S,Mead M. Triple-negative breast cancer: advancements in characterization and treatment approach.Curr Opin Obstet Gynecol.2016 28(1):59-69. 2.Lyons TG,Robson ME.Resurrection of PARP Inhibitors in Breast Cancer. J Natl Compr Canc Netw.2018 16(9):1150-1156. ...
Chemotherapy has long been the cornerstone of treatment for triple-negative breast cancer. Recently, the integration of PARPis into treatment regimens has shown promise, particularly in patients with BRCA1/2 mutations, due to their impaired DNA repair mechanisms via HR [15]. PARP inhibitors, when...
参考文献:Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncol.
1.第一项研究是一项meta分析,关于BRCA突变对乳腺癌预后影响的研究有很多,结果也不完全一致,我选择这项研究的原因有两个:第一个是这项研究的发表日期是2021年;第二个是研究发表在Breast cancer research and treatment这个杂志上,是乳腺癌领域的老牌杂志。
Faculty of Medicine, University of Southampton, Southampton University Hospitals NHS Trust, Southampton SO16 6YD, UK; 7Breakthrough Breast Cancer Research Unit, King's College, London SE1 9RT, UK BACKGROUND: Triple-negative (TN) tumours are the predominant breast cancer subtype in BRCA1 mutation...
The triple-negative breast cancer subtype made up most patients enrolled in this study. Roughly 80% of patients have triple-negative disease compared with hormone receptor-positive in HER2-negative breast cancer.The next slide will show you the outcome that was reported at a March 2022 ESMO [...